{"id":"drug-carboplatin","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Myelosuppression"},{"rate":"20-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Neuropathy"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carboplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.","oneSentence":"Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:17.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Breast cancer"},{"name":"Lung cancer"}]},"trialDetails":[{"nctId":"NCT04166409","phase":"PHASE3","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-31","conditions":"Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma","enrollment":170},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT05198830","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-15","conditions":"Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":42},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT03997370","phase":"PHASE1","title":"Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2020-01-15","conditions":"Malignant Solid Neoplasm","enrollment":318},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07493980","phase":"PHASE2","title":"Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-03","conditions":"NSCLC Stage II","enrollment":54},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT06538038","phase":"","title":"Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients","status":"RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2024-09-17","conditions":"Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer","enrollment":538},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":"Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8","enrollment":108},{"nctId":"NCT03871257","phase":"PHASE3","title":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-15","conditions":"Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma","enrollment":165},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":544},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":"Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma","enrollment":1},{"nctId":"NCT07138755","phase":"PHASE2","title":"The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-29","conditions":"NSCLC, Sintilimab, Adaptive Radiotherapy","enrollment":35},{"nctId":"NCT05108870","phase":"PHASE1, PHASE2","title":"TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-07-17","conditions":"Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":98},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT04216316","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-14","conditions":"Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":"High Grade Glioma, CNS Tumor","enrollment":52},{"nctId":"NCT05980169","phase":"NA","title":"The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Augusta University","startDate":"2023-11-29","conditions":"Gynecologic Cancer, Neuropathy;Peripheral","enrollment":80},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT05789082","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-20","conditions":"Non-Small Cell Lung Cancer","enrollment":320},{"nctId":"NCT04415944","phase":"PHASE2","title":"Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-20","conditions":"Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III","enrollment":10},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT04253964","phase":"PHASE2","title":"Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Nonsmall Cell Lung Cancer, Performance Status","enrollment":105},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT04016142","phase":"PHASE2","title":"Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2020-07-15","conditions":"Locally Advanced Cancer, Cervical Cancer","enrollment":21},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07230691","phase":"","title":"A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":380},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":"HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients","enrollment":55},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT03003962","phase":"PHASE3","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-01-02","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":669},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT07457528","phase":"PHASE2","title":"Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-12","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05973773","phase":"PHASE3","title":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-12-18","conditions":"Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation","enrollment":285},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT06984861","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-13","conditions":"Oropharyngeal Carcinoma","enrollment":74},{"nctId":"NCT07209189","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-04","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer","enrollment":75},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT07448922","phase":"PHASE2","title":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","startDate":"2026-03-25","conditions":"Advanced Gynecological Malignancies","enrollment":290},{"nctId":"NCT06159790","phase":"PHASE3","title":"A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"SUSPENDED","sponsor":"Sandoz","startDate":"2024-04-29","conditions":"Metastatic NSCLC","enrollment":218},{"nctId":"NCT05068232","phase":"PHASE2","title":"Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2022-08-19","conditions":"Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer","enrollment":49},{"nctId":"NCT06318897","phase":"PHASE2","title":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-29","conditions":"Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer","enrollment":28},{"nctId":"NCT05184712","phase":"PHASE3","title":"Phase 3 Clinical Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-01-25","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":322},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT07028281","phase":"PHASE2","title":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-08","conditions":"Malignant Solid Tumors","enrollment":120},{"nctId":"NCT03057106","phase":"PHASE2","title":"Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2017-03-28","conditions":"Lung Cancer Metastatic","enrollment":301},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT06457503","phase":"PHASE4","title":"A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2024-11-01","conditions":"Nasopharyngeal Cancer Recurrent","enrollment":100},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT05566795","phase":"PHASE3","title":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","status":"RECRUITING","sponsor":"Day One Biopharmaceuticals, Inc.","startDate":"2023-02-27","conditions":"Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma","enrollment":400},{"nctId":"NCT05797168","phase":"PHASE1, PHASE2","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-06-05","conditions":"Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer","enrollment":506},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06103864","phase":"PHASE3","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-23","conditions":"Breast Cancer","enrollment":625},{"nctId":"NCT07033819","phase":"PHASE2","title":"Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-25","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Drug: carboplatin","genericName":"Drug: carboplatin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription. Used for Ovarian cancer, Breast cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}